Ryan Zimmerman, another medtech analyst at BTIG, called attention to Carlsmed in a report issued October 12.

Carlsmed has had quite a bit to celebrate in the past year. Most recently, the Carlsbad, CA-based medtech company launched the aprevo patient-specific spine technology and also announced that the technology is eligible for reimbursement through a new technology add-on payment (NTAP).

The company’s aprevo devices are FDA cleared and designed to improve the standard of care for the surgical treatment of adult patients with spinal malalignment. Carlsmed uses patient data and the company's Data to Device digital technologies to create optimal surgical plans and personalized aprevo spine fusion devices to align with the surgeon’s goals for each patient.

Carlsmed's aprevo technology was recognized during the North American Spine Society (NASS) meeting in September with the Spine Technology Award.

"By intentionally creating implants to fit a patient's own bone, we can start to realize the potential of personalized medicine and its benefits to each individual patient,” said Vijay Yanamadala, MD, director of spinal deformity surgery at Hartford HealthCare, and one of the neursurgeons who collaborated with Carlsmed and patients to complete one of the first aprevo procedures earlier this year as part of a limited clinical release. “My goal is for the aprevo surgery to be the last spine surgery that a patient will ever need.”

In July, Carlsmed partnered with the International Spine Study Group Foundation to collect data on surgical treatment with personalized interbody devices. Long-term outcomes data will be collected to assess the role of aprevo devices in improving patient outcomes and reducing postoperative complications.

The company raised $10 million in a series A financing round in December 2020 to support the commercial launch of the technology.